Exelixis Inc (EXEL) — Analysis Summary
Exelixis Inc (EXEL) has a market cap of $13.69B with year-over-year revenue growth of +7.0%. Net margin stands at 33.7%. The stock trades at a P/E ratio of 15.9.
Key Takeaways
- Revenue changed +7.0% year-over-year
- Net margin of 33.7%
- P/E ratio of 15.9
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, EXEL posted revenue growth of +7.0% and trades at a P/E of 15.9.
Exelixis Inc (EXEL)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsWatch List
Some caution signals are active and should be weighed alongside the valuation work.
Gross margin at 96.5% — verify: very few businesses sustain >90% gross margin outside pure software/IP
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
1,077
Headquarters
ALAMEDA, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.